Use of spironolactone-based composition that exhibits an inhibitory action on t-lymphocyte activation which is usefule for preventing and/or treating multiple sclerosis

Abstract

The present invention relates to the use of spironolactone for the preparation of a pharmaceutical composition intended for preventing and / or treating multiple sclerosis. Alternatively, the invention relates to the use of spironolactone directly in T-lymphocytes or dendritic cells obtained from a blood sample taken from a patient and then injected back into the circulation. Therefore, the present invention relates to the use of a composition comprising spironolactone that can be used in the treatment of multiple sclerosis, which covers the administration of spironolactone directly or lymphocytes pre-treated with spironolactone, or dendritic cells to individuals requiring such treatment. Spironolactone is an orally administered drug that is less expensive than many of the treatments available for MS and, furthermore, has the advantage of being a known compound already used in humans for extended periods and therefore the adverse effects thereof have been described in clinical studies.

Description

FIELD OF INVENTION[0001]The present invention relates to the use of a composition comprising spironolactone for the treatment of multiple sclerosis.BACKGROUND OF THE INVENTION[0002]Multiple Sclerosis (MS) is one of the most common neurological disorders worldwide and one of the major neurological non-traumatic disability causes in young adults, more common in women than men, the first symptoms appearing around 30 years of age. Multiple sclerosis is a progressive disease, of autoimmune inflammatory origin, characterized by the loss or damage of myelin sheath coating nervous fibers of the Central Nervous System (CNS), which is substituted with connective tissue plaques. This generates an alteration in conduction of nervous impulse and said alteration is the source of the most common symptoms of the disease, such as muscular weakness, spasticity or motor dysfunction, visual alterations, equilibrium problems, urinary dysfunction, constipation, and cognitive or behavioral anomalies (Atla...

AI Technical Summary

Benefits of technology

The present invention is about using spironolactone to make a medicine or a treatment for multiple sclerosis. This treatment can involve giving spironolactone to patients or taking T-lymphocytes from a patient, treating them with spironolactone, and then putting them back into the patient. This treatment is cost-effective and has been tested in humans before. The invention also covers using spironolactone to modify T-lymphocytes or dendritic cells for this treatment.

Problems solved by technology

In spite of the multiple drugs previously described, many MS patients do not respond in a favorable way, either because they have no significant effect on the course of the disease or because they show important side effects.

Also, the majority of drugs used up until now, are parenteral drugs, which would imply a higher complexity and discomfort for its application.

Images